AR129270A1 - Profármacos y usos de los mismos - Google Patents

Profármacos y usos de los mismos

Info

Publication number
AR129270A1
AR129270A1 ARP230101137A ARP230101137A AR129270A1 AR 129270 A1 AR129270 A1 AR 129270A1 AR P230101137 A ARP230101137 A AR P230101137A AR P230101137 A ARP230101137 A AR P230101137A AR 129270 A1 AR129270 A1 AR 129270A1
Authority
AR
Argentina
Prior art keywords
dkp
thz
formula
relates
prodrugs
Prior art date
Application number
ARP230101137A
Other languages
English (en)
Spanish (es)
Inventor
Bhavesh Premdjee
Jesper F Lau
Cecilie Mia Jrgensen
Lennart Lykke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR129270A1 publication Critical patent/AR129270A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP230101137A 2022-05-10 2023-05-09 Profármacos y usos de los mismos AR129270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22172545 2022-05-10

Publications (1)

Publication Number Publication Date
AR129270A1 true AR129270A1 (es) 2024-08-07

Family

ID=81940650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101137A AR129270A1 (es) 2022-05-10 2023-05-09 Profármacos y usos de los mismos

Country Status (7)

Country Link
US (1) US20250304645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522220A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517672A (cg-RX-API-DMAC7.html)
CN (1) CN119173275A (cg-RX-API-DMAC7.html)
AR (1) AR129270A1 (cg-RX-API-DMAC7.html)
TW (1) TW202346324A (cg-RX-API-DMAC7.html)
WO (1) WO2023217744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120659805A (zh) * 2023-10-31 2025-09-16 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用
WO2026052063A1 (en) * 2024-09-06 2026-03-12 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Glp-1 polypeptide prodrugs and uses thereof
WO2026139053A1 (zh) * 2024-12-27 2026-07-02 深圳信立泰药业股份有限公司 一种包含glp-1化合物的药物组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
ES2810153T3 (es) 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Also Published As

Publication number Publication date
EP4522220A1 (en) 2025-03-19
CN119173275A (zh) 2024-12-20
JP2025517672A (ja) 2025-06-10
US20250304645A1 (en) 2025-10-02
WO2023217744A1 (en) 2023-11-16
TW202346324A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
ES2657687T3 (es) Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales
AR126076A1 (es) Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES2683860T3 (es) Compuestos de succinato con permeabilidad celular novedosos
AR035365A1 (es) Compuesto peptidico que comprende un centro inhibidor de la metionina aminopeptidasa 2 (metap-2) y su uso para preparar un medicamento
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
PE20240630A1 (es) Profarmacos de glp-1 y usos de los mismos
DE69832982T2 (de) Dolastatin 15 derivate
AR033383A1 (es) Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
AR115283A1 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoe
ES2670394T3 (es) Inhibidores de ciclofilinas para utilizar en la prevención y/o el tratamiento de patologías virales o infecciones
JPWO2003070754A1 (ja) ヒストン脱アセチル化酵素阻害剤およびその製造方法
BRPI0708299A2 (pt) composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas
AR005827A1 (es) Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion
AU2005265164A2 (en) Non-natural amino acids
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
CA2064592A1 (fr) Derives d'amino-acides, leur procede de preparation et leur application therapeutique
WO2019110837A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
CO2026000927A2 (es) Derivado de amida sustituido con heterociclilalquinilo, método de preparación del mismo y uso del mismo
AR030197A1 (es) Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
ES2641992T3 (es) Compuestos de pirimidina bicíclicos sustituidos
AR004264A1 (es) Compuesto beta-amino ester de alcoholes perfumados para su uso en composiciones para lavado de ropa y limpieza de superficies duras, proceso depreparacion, metodo de uso.
US20200390777A1 (en) Lipid prodrugs of mycophenolic acid and uses thereof
JP2014530882A5 (cg-RX-API-DMAC7.html)
EP3720471A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Legal Events

Date Code Title Description
FB Suspension of granting procedure